Methods for treating ocular diseases with brolucizumab
A method is provided for reducing the treatment burden for patients who have an intraocular neovascular disorder, the method comprising administering a therapeutically effective amount of VEGF antagonist on a dosing schedule that includes treatment intervals of 8 and/or 12 weeks.
1. A method for treating neovascular age-related macular degeneration (nAMD) in a patient, the method comprising administering to the patient three individual doses of a VEGF antagonist at 4-week intervals, and thereafter administering to the patient an additional dose every 12 weeks and monitoring the patient's best-corrected visual acuity (BCVA) for a decrease of letters due to nAMD disease activity to determine if the patient should receive a dose more frequently than once every 12 weeks, wherein each dose of the VEGF antagonist is at least 3 mg and the VEGF antagonist is brolucizumab.
2. The method of claim 1 , wherein each dose of the VEGF antagonist is 3 mg.
3. The method of claim 2 , wherein each dose of the VEGF antagonist is administered as a 50 μL intravitreal injection.
4. The method of claim 1 , wherein each dose of the VEGF antagonist is 6 mg.
5. The method of claim 4 , wherein each dose of the VEGF antagonist is administered as a 50 μL intravitreal injection.
6. The method of claim 1 , wherein a 12 week treatment interval is switched to an 8 week treatment interval if the patient's BCVA decreases ≥5 letters due to nAMD disease activity.